Get the Stockscreener App
8.56
0.59%
0.05
Pre-market:
8.73
0.17
+1.99%
Diamedica Therapeutics Inc stock is traded at $8.56, with a volume of 281.67K.
It is up +0.59% in the last 24 hours and up +27.57% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$8.51
Open:
$8.51
24h Volume:
281.67K
Relative Volume:
0.68
Market Cap:
$445.78M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-16.15
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
-6.14%
1M Performance:
+27.57%
6M Performance:
+103.81%
1Y Performance:
+57.06%
1-Day Range:
$7.97
$8.88
1-Week Range:
$7.76
$9.1599
52-Week Range:
$3.19
$9.23
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.56 | 443.18M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-30-25 | Initiated | TD Cowen | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
What dividend safety score for DiaMedica Therapeutics Inc. stock2025 Risk Factors & Fast Gain Stock Tips - Newser
What drives DiaMedica Therapeutics Inc stock priceAnalyst Downgrades & Free Lightning Fast Capital Gains - earlytimes.in
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth - Yahoo Finance
Is DiaMedica Therapeutics Inc. stock in correction or buying zoneJuly 2025 Patterns & Fast Exit and Entry Trade Guides - BỘ NỘI VỤ
Private Capital's DiaMedica Therapeutics Inc(DMAC) Holding History - GuruFocus
Why DiaMedica Therapeutics Inc. stock is a value investor pickJuly 2025 Drop Watch & Smart Allocation Stock Tips - BỘ NỘI VỤ
There is no way DiaMedica Therapeutics Inc (DMAC) can keep these numbers up - Setenews
Dir Parsons Acquires 12,000 Of DiaMedica Therapeutics Inc [DMAC] - TradingView
[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
DiaMedica In Focus After 52-Week High And FDA Meeting Progress - RTTNews
How DiaMedica Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - inkl
HC Wainwright Has Bearish Forecast for DMAC FY2025 Earnings - Defense World
Smart tools for monitoring DiaMedica Therapeutics Inc.’s price actionPortfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Why analysts remain bullish on DiaMedica Therapeutics Inc. stock2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Published on: 2025-11-19 22:42:15 - newser.com
Will DiaMedica Therapeutics Inc. stock return to pre crisis levels2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Published on: 2025-11-19 13:58:17 - newser.com
Is DiaMedica Therapeutics Inc. stock supported by innovation pipelineTake Profit & Fast Momentum Entry Tips - newser.com
This trade activity should not be overlooked: DiaMedica Therapeutics Inc (DMAC) - Setenews
Is DiaMedica Therapeutics Inc. still worth holding after the dip2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - newser.com
What is HC Wainwright’s Estimate for DMAC Q1 Earnings? - Defense World
Published on: 2025-11-18 23:37:26 - newser.com
Can DiaMedica Therapeutics Inc. stock outperform in 2025 bull marketTrade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Why DiaMedica Therapeutics Inc. stock remains on watchlistsRate Hike & Safe Swing Trade Setups - newser.com
Short interest data insights for DiaMedica Therapeutics Inc.2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
DMAC News Today | Why did DiaMedica Therapeutics stock go up today? - MarketBeat
Has DiaMedica Therapeutics Inc. formed a bullish divergence2025 Price Momentum & Community Driven Trade Alerts - newser.com
Developing predictive dashboards with DiaMedica Therapeutics Inc. dataStop Loss & Fast Momentum Entry Tips - newser.com
DiaMedica Therapeutics Inc Stock Analysis and ForecastSector-Based Investing & Low Risk Trading Growth - earlytimes.in
What Futures Contracts Reveal About Globesecure Technologies Limiteds Near Term VolatilityUtilities Sector Analysis & Small Budget Investment Tips - earlytimes.in
Can DiaMedica Therapeutics Inc. stock double in next 5 yearsCEO Change & Stock Market Timing Techniques - newser.com
DiaMedica Therapeutics Reports Q3 2025 Financial Results - MSN
Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (NASDAQ:DMAC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Cantor Fitzgerald Initiates Coverage of DiaMedica Therapeutics (DMAC) with Overweight Recommendation - MSN
Visual analytics tools that track DiaMedica Therapeutics Inc. performanceJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Using flow based indicators on DiaMedica Therapeutics Inc.Exit Point & Consistent Return Investment Signals - newser.com
Backtesting results for DiaMedica Therapeutics Inc. trading strategies2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
DMAC: Cantor Fitzgerald Initiates Coverage with Overweight Ratin - GuruFocus
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2025 Earnings Call Transcript - Insider Monkey
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):